NCT04812379 - Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP) | Biotech Hunter

Enrollment

535

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

September 13, 2023

Study Completion Date

June 21, 2024

Conditions

Bipolar Disorder I

Interventions

DRUG

Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)

The usual dose in adults is 400 mg of aripiprazole administered intramuscularly in the gluteal or deltoid muscle as a single dose once every 4 weeks. The dose may be decreased to 300 mg based on the patient's symptoms and tolerability.

Trial Locations (1)

540-0021

Pharmacovigilance Department, Osaka